The comparators presented in the following table have been deemed to be appropriate by clinical experts. Comparators may be recommended (appropriate) practice versus actual practice. Comparators are not restricted to drugs, but may be devices or procedures. Costs are manufacturer list prices, unless otherwise specified. Existing Product Listing Agreements are not reflected in the table and as such may not represent the actual costs to public drug plans.
Table 6CADTH Common Drug Review Cost Comparison Table for Opioid Use Disorder
View in own window
| Drug/ Comparator | Strength | Dosage Form | Price ($) | Recommended Dosage | Average Cost per Month ($) | Average Cost per Year ($) |
|---|
| Buprenorphine (Sublocade) | 100 mg/0.5 mL 300 mg/1.5 mL | Subcutaneous injection | 550.0000a 550.0000a | 300 mg monthly for two months, followed by 100 mg monthly maintenance doses. The maintenance dose can be increased to 300 mg if satisfactory clinical response is not demonstrated | 550 | 6,600 |
| Buprenorphine (Probuphine) | 80 mg × 4 | Subdermal implant | 1,495.0000b | 4 implants, may be repeated once after six months | 249 | 2,990 |
| Buprenorphine/ Naloxone (generics) | 2 mg/0.5 mg 8 mg/2 mg | Sublingual tablet | 0.6675 1.1825 | 12 mg to 16 mg per day | 72 to 77 | 864 to 920 |
| Methadone (Metadol-D) | 1 mg 5 mg 10 mg 25 mg 1 mg/mL 10 mg/mL | Tablet Tablet Tablet Tablet Solution Solution | 0.1769b 0.5896b 0.9432b 1.7526b 0.1106b 0.1500 | 60 mg to 120 mg dailyd | 135 to 271 27 to 55 | 1,625 to 3,249 329 to 657 |
| Naltrexone (generics) | 50 mg | Tablet | 2.8075 | 50 mg daily, 100 mg every other day, or 150 mg every third day | 85 | 1,025 |
Note: All prices are from the Ontario Drug Benefit Formulary13 (accessed January 2019) unless otherwise indicated and do not include dispensing fees.
- a
Manufacturer-submitted price.2
- b
CADTH Common Drug Review Probuphine pharmacoeconomic review report.18
- c
Saskatchewan Drug Plan (accessed January 2019).19
- d
Canadian Research initiative on substance misuse national guideline for the clinical management of opioid use disorder.17
